Attorney Docket No. 11823-002630US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Cary L. Queen et al.

Serial No.: 08/484,537

Filed: June 7, 1995

For: IMPROVED HUMANIZED

ANTIBODIES

Examiner: Julie E. Reeves

Art Unit: 1806

INFORMATION DISCLOSURE

STATEMENT UNDER

37 CFR §1.97 and §1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. These references were cited in the oppositions filed against Protein Design Labs, Inc.'s corresponding EP Patent. As suggested by the Examiners, this submission does not include all of the opposition statements. Also, all references cited in the attached form 1449 have been previously cited in a copending related application, and duplicate copies of documents are therefore not being provided herewith.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior

Cary L. Queen et al. Serial No.: 08/484,537

Page 2

. .

to the first Office Action on the merits. However, if a fee is required, the Commissioner is authorized to charge such fee to Deposit Account No. 20-1430. Please charge any additional fees or credit any overpayment to the above-noted Deposit Account.

Respectfully submitted,

William M. Smith Reg. No. 30,223

WMS:agh TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834 (415) 326-2400 Fax (415) 326-2422 WMS\PDL\2600\2630B.IDS

